BiVictriX Therapeutics plc Stock

BVX

GB00BNXH3K91

Biotechnology & Medical Research

OTC Markets Traded

Latest news : BiVictriX Therapeutics plc

25-06-12	BiVictriX Therapeutics plc Reports Earnings Results for the Full Year Ended December 31, 2024	CI
25-05-27	Bivictrix Limited Announces Termination of Mrs. Susan Day Lowther as Director, Effective May 23, 2025	CI
25-05-27	BiVictriX Therapeutics plc Appoints Michael Glen Kauffman as Director, Effective May 23, 2025	CI
24-09-09	Bivictrix Therapeutics optimistic about BVX002 after in vivo testing	AN
24-09-09	BiVictriX's Ovarian Cancer Drug Conjugate Demonstrates Tumor Growth Inhibition	MT
24-08-12	Stocks rise as focus moves to economic data	AN
24-08-12	Bivictrix Therapeutics to delist as AIM offers insufficient liquidity	AN
24-08-12	AIM WINNERS & LOSERS: Global Petroleum jumps on potential Namibia deal	AN
24-08-12	BiVictriX Plans Delisting from London's AIM in September	MT
24-08-12	Bharti Global to build near 25% stake in BT	AN
24-08-01	Earnings Flash (BVX.L) BIVICTRIX THERAPEUTICS Reports H1 Loss GBX-1.79	MT
24-08-01	BiVictriX Therapeutics plc Reports Earnings Results for the Half Year Ended June 30, 2024	CI
24-06-20	BiVictriX Therapeutics Plc Reports Earnings Results for the Full Year Ended December 31, 2023	CI

More news

Press Releases: BiVictriX Therapeutics plc

24-09-11	BiVictriX Therapeutics plc Shares now trading on JP Jenkins	EQ
23-10-06	BiVictriX Therapeutics appoints combined CFO/CBO to boost out-licensing efforts	AQ
23-09-20	BiVictriX Therapeutics "looking really healthy" after positive first half	AQ
23-08-23	BiVictriX Therapeutics passes "exciting milestone" with US patent for BVX001	AQ
23-03-30	BiVictriX Therapeutics to "continue seeking out positive relationships"	AQ

More press releases

Managers and Directors: BiVictriX Therapeutics plc

Manager	Title	Age	Since
Tiffany Thorn CEO	Chief Executive Officer	39	2015-12-31
Adrian Howd DFI	Director of Finance/CFO	54	2023-10-02
Alison Halsall SEC	Corporate Secretary	-	2023-10-12

Director	Title	Age	Since
Tiffany Thorn BRD	Director/Board Member	39	2015-12-31
Susan Lowther BRD	Director/Board Member	67	2021-09-21
William Paris BRD	Director/Board Member	75	2021-09-21

More insiders

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
BIVICTRIX THERAPEUTICS PLC	+17.65%	+33.33%	-	-	10.49M
LONZA GROUP AG	+0.58%	+2.06%	+3.90%	+10.40%	50.73B
REVOLUTION MEDICINES, INC.	-2.22%	-1.25%	+391.53%	+591.38%	39.73B
IQVIA HOLDINGS INC.	-0.54%	+0.39%	+27.67%	-3.89%	34.69B
BEONE MEDICINES AG	-1.36%	+0.35%	+19.34%	+58.83%	33.21B
CELLTRION, INC.	+1.21%	-4.58%	+3.00%	+37.03%	26.76B
ASCENDIS PHARMA A/S	-1.81%	-1.48%	-	-	16.8B
MEDPACE HOLDINGS, INC.	+0.51%	-3.47%	+66.38%	+125.61%	15.37B
EUROFINS SCIENTIFIC SE	+0.23%	-0.58%	+13.80%	+19.56%	13.78B
ICON PUBLIC LIMITED COMPANY	-0.62%	-3.09%	+11.43%	-29.93%	12.85B
Average	+1.36%	-0.83%	+67.13%	+101.12%	27.1B
Weighted average by Cap.	-0.48%	-0.23%	+82.75%	+126.14%

See all sector performances

BiVictriX Therapeutics plc is a drug discovery and development company. The Company is focused on leveraging clinical experience to develop highly selective cancer therapeutics. The Company generates a proprietary pipeline of Bi-Cygni Antibody Drug Conjugate (ADC) therapeutics which are designed to selectively target cancer-specific antigen pairs, or Bi-Cygni fingerprints, on tumour cells, which are largely absent from healthy cells. The Company utilizes these novel Bi-Cygni fingerprints, together with the Companyâ€™s novel Antibody Drug Conjugate therapeutic design, to develop therapeutics to target cancers. Its pipeline includes BVX001, BVX002 and BVX003. Its lead program: BVX001 is a Bi-Cygni ADC designed to target the cancer-specific Bi-Cygni fingerprint, CD7 x CD33, found on the cancer cells of approximately 25-30% of patients with Acute Myeloid Leukaemia (AML), and in subpopulations of cancer cells from patients with other haematological cancers.

Employees

Sector

Biotechnology & Medical Research

More about the company